Statistik Asas
| LEI | 969500UDH342QLTE1M42 |
| CIK | 749660 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to iCAD, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-09341 iCAD, INC. (Exact name of registrant as specified in its charter) |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 17, 2025 iCAD, INC. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD · Acquisition contributes iCAD's commercial, technology, and regulatory capabilities · The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutions · The combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies Los Angeles, CA – July 17, 2025, RadNet, Inc. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF iCAD, INC. ARTICLE I EXHIBIT A AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF iCAD, INC. ARTICLE I The name of the corporation is iCAD, Inc. (the "Corporation"). ARTICLE II The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of the registered agent of the corporation at that address is Corpo |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
AMENDED AND RESTATED iCAD, INC. Table of Contents AMENDED AND RESTATED BYLAWS OF iCAD, INC. Table of Contents Page ARTICLE 1 CORPORATE OFFICES 4 1.1 Registered Office. 4 1.2 Other Offices. 4 ARTICLE 2 MEETINGS OF STOCKHOLDERS 4 2.1 Place of Meetings. 4 2.2 Annual Meeting. 4 2.3 Special Meeting. 4 2.4 Notice of Stockholders’ Meetings. 5 2.5 Manner of Giving Notice; Affidavit of Notice. 5 2.6 Validation of Meetings; Waiver of Notice; Consent. 5 2.7 |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 17, 2025 |
As filed with the Securities and Exchange Commission on July 17, 2025 As filed with the Securities and Exchange Commission on July 17, 2025 Registration No. |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 14, 2025 iCAD, INC. |
|
| July 8, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 333-287005 The following press release was publicly disseminated by iCAD, Inc. (the “Company”) on July 8, 2025 (the “Press Release”). FOR IMMEDIATE RELEASE iCAD Announce |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| July 1, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 333-287005 The following letter was distributed by iCAD, Inc. (the “Company”) on July 1, 2025 to certain stockholders of the Company. June 30, 2025 Dear Stockholder, iCA |
|
| June 16, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 333-287005 The following set of Frequently Asked Questions (“FAQs”) were distributed by iCAD, Inc. (“iCAD”) to its employees on June 13, 2025. FAQ – iCAD Employees Certa |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2025 iCAD, INC. |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2025 iCAD, INC. |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2025 iCAD, INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2025 iCAD, INC. |
|
| May 13, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following is an excerpt of the transcript of the earnings release conference call held by RadNet, Inc. on May 12, 2025 as well as respons |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 13, 2025 |
iCAD Reports Financial Results for First Quarter Ended March 31, 2025 Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H. – May 13, 2025 – iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025. Fir |
|
| May 13, 2025 |
iCAD Reports Financial Results for First Quarter Ended March 31, 2025 Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H. – May 13, 2025 – iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025. Fir |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-09 |
|
| April 29, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following presentation was given to employees of iCAD, Inc. on April 29, 2025. No Offer or Solicitation This communication does not constitute an offer to |
|
| April 29, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following was used at an iCAD, Inc. employee townhall held on April 29, 2025, in connection with RadNet, Inc.’s proposed acquisition of i |
|
| April 29, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following press release was disseminated by iCAD, Inc. on April 29, 2025. iCAD Collaborates with Microsoft to provide access to its Mammography Solutions |
|
| April 24, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: On April 17, 2025, the following article was published by Medical Device Network in connection with the proposed acquisition of iCAD, Inc. Ra |
|
| April 24, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: On April 17, 2025, the following article was published by Healthcare Business International in connection with the proposed acquisition of iC |
|
| April 23, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following is a transcript for a presentation given by Dana Brown, President and Chief Executive Officer of iCAD, Inc. (“iCAD”), and Mark Koeniguer, Chief |
|
| April 17, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: On April 17, 2025, the following article was published by STAT in connection with RadNet, Inc.’s proposed acquisition of iCAD, Inc. To speed |
|
| April 17, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following presentation was used on April 16, 2025, in connection with the proposed merger of RadNet, Inc. and iCAD, Inc. April 16, 2025 | |
|
| April 17, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following is a transcript from the Media Roundtable held on April 16, 2025, in connection with RadNet, Inc.’s proposed acquisition of iCA |
|
| April 17, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following is a transcript from an investor call held on April 16, 2025, in connection with RadNet, Inc.’s proposed acquisition of iCAD, I |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to members of the media. To: Key journalists Subject: RadNet/DeepHealth announce intent to acqui |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to members of the media. To: Selected Media Subject: Media Roundtable Invitation on RadNet/DeepH |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: On April 15, 2025, DeepHealth, Inc., RadNet, Inc’s wholly-owned subsidiary, published the following post on LinkedIn in connection with the p |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following speaking points were shared with RadNet, Inc. employees. · Thank you for your inquiry regarding the recent RadNet announcement |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to members of the media. To: Global AI/Tech/M&A reporter pitch note Subject: RadNet/DeepHealth a |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following partner speaking points were shared with RadNet, Inc. employees. 1. RadNet, Inc. (“RadNet”) Has Entered Into a Definitive Agree |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: On April 15, 2025, RadNet, Inc published the following post on LinkedIn in connection with the proposed acquisition of iCAD, Inc. 1 2 No Offe |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following speaking points were shared with RadNet, Inc. employees. · I am pleased to share that RadNet has entered into a definitive agre |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to members of the media. To: Industry reporters pitch note Subject: DeepHealth announce intent t |
|
| April 16, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to its business partners in connection with the proposed acquisition of iCAD, Inc. Subject: RadN |
|
| April 15, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following message was sent by RadNet, Inc. to employees of DeepHealth, Inc., RadNet, Inc’s wholly-owned subsidiary. RadNet to Acquire iCA |
|
| April 15, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following speaking points were shared with RadNet, Inc. employees. · Thank you for your inquiry regarding the recent RadNet announcement |
|
| April 15, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Commission File Number: 001-09341 Explanatory Note: The following information was provided in connection with the proposed merger of RadNet, Inc. with iCAD, Inc. Strategy and Product Q1. Why is |
|
| April 15, 2025 |
Form of Voting and Support Agreement. VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is entered into as of [●], 2025, by and among RadNet, Inc. |
|
| April 15, 2025 |
AGREEMENT AND PLAN OF MERGER by and among RADNET, INC. TRIO MERGER SUB, INC. and iCAD, INC. dated as of April 15, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Interpretation. 16 ARTICLE II THE MERGER 17 Section 2.1 The Merger 17 Section 2.2 Closing 17 Section 2.3 Effective Time 17 Section 2.4 Effects of the Transaction 17 Section 2.5 Intended Tax Treatm |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 15, 2025 iCAD, INC. |
|
| April 15, 2025 |
FOR IMMEDIATE RELEASE RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer · The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer · The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed |
|
| April 15, 2025 |
Filed by RadNet, Inc. Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD Inc. Filer’s Commission File Number: 001-09341 Explanatory Note: The following email was sent by RadNet, Inc. to employees of DeepHealth, Inc., RadNet, Inc’s wholly-owned subsidiary. From: Naiara Ma |
|
| April 15, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following are social media posts made by iCAD, Inc. and management of iCAD, Inc. on April 15, 2025. No Offer or Solicitation This communication does not c |
|
| April 15, 2025 |
AGREEMENT AND PLAN OF MERGER by and among RADNET, INC. TRIO MERGER SUB, INC. and iCAD, INC. dated as of April 15, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Interpretation. 16 ARTICLE II THE MERGER 17 Section 2.1 The Merger 17 Section 2.2 Closing 17 Section 2.3 Effective Time 17 Section 2.4 Effects of the Transaction 17 Section 2.5 Intended Tax Treatm |
|
| April 15, 2025 |
Form of Voting and Support Agreement. VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is entered into as of [●], 2025, by and among RadNet, Inc. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 15, 2025 iCAD, INC. |
|
| April 15, 2025 |
FOR IMMEDIATE RELEASE RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer · The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer · The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed |
|
| April 15, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following are talking points distributed by iCAD, Inc. on April 15, 2025. Strategy and Product Q1. Why is iCAD being acquiring by RadNet, and how does thi |
|
| April 15, 2025 |
Filed by iCAD, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: iCAD, Inc. Commission File No.: 0000749660 The following presentation was given to employees of iCAD, Inc. on April 15, 2025. No Offer or Solicitation This communication does not constitute an offer to |
|
| March 31, 2025 |
Lease between Anita R. Jacques Revocable Trust, dated January 6, 2024 and iCAD, Inc. Exhibit 10.19 Lease Agreement Under the ownership under the trust of Anita R. Jacques Revocable Trust Dated 03/31/1994, of 211 Naticook Rd. Merrimack, NH. County of Hillsborough, and State of New Hampshire, (Lessor), hereby leases to iCAD, Inc. of 98 Spit Brook Road #100, Nashua, NH 03062 (Lessee). the Premises on the following terms: 1. PREMISES: 3,054 +/- Square feet in the building located at 2 |
|
| March 31, 2025 |
iCAD, Inc. Insider Trading Policy Exhibit 19.1 iCAD, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Company Information and Certain Transactions in Company Securities Purpose This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of iCAD, Inc., a Delaware corporation (including subsidiaries where applicable, the “Company”) and the handling of material conf |
|
| March 31, 2025 |
EXHIBIT 21.1 Subsidiaries of iCAD, Inc. Name Jurisdiction of Incorporation/Organization iCad France, LLC Delaware |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-0934 |
|
| March 31, 2025 |
Description of Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, iCAD, Inc. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share (“Common Stock). General The following description of our capita |
|
| March 19, 2025 |
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 Exhibit 99.1 iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 NASHUA, N.H. – March 19, 2025 – iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter a |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 19, 2025 iCAD, INC. |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 27, 2025 iCAD, INC. |
|
| January 27, 2025 |
iCAD Pre-Announces Estimated Q4 2024 Revenue iCAD to Participate in the BTIG at Snowbird: 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference NASHUA, NH. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2024 |
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 Exhibit 99.1 iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 NASHUA, N.H. – November 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended S |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2024 iCAD, INC. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2024 iCAD, INC. |
|
| August 13, 2024 |
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024 Exhibit 99.1 iCAD Reports Financial Results for Second Quarter Ended June 30, 2024 NASHUA, N.H. – August 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, |
|
| July 2, 2024 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) iCAD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 457(c) and 457(h) 4 |
|
| July 2, 2024 |
The iCAD, Inc. 2024 Omnibus Equity Incentive Plan iCAD, INC. 2024 OMNIBUS EQUITY INCENTIVE PLAN (Effective July 13, 2024) TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 “Cause” 2 2.7 “CEO” 2 2.8 “Change in Contro |
|
| July 2, 2024 |
The iCAD, Inc. 2016 Stock Incentive Plan, as amended iCAD, INC. 2016 STOCK INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iCad, Inc. 2016 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to align the interests of the officers, employees, Non-Employee Directors and Consultants of iCad, Inc. (the “Company”) and its Subsidiaries upon whose judgment, initiative and efforts the Comp |
|
| July 2, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 As filed with the Securities and Exchange Commission on July 2, 2024 Registration No. |
|
| June 14, 2024 |
iCAD, Inc. 2024 Omnibus Equity Incentive Plan iCAD, INC. 2024 OMNIBUS EQUITY INCENTIVE PLAN (Effective June 13, 2024) TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 “Cause” 2 2.7 “CEO” 2 2.8 “Change in Contro |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2024 iCAD, INC. |
|
| May 15, 2024 |
iCAD Reports Financial Results for First Quarter Ended March 31, 2024 Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2024 NASHUA, N.H. – May 15, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2024 iCAD, INC. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 29, 2024 |
iCAD, Inc. Insider Trading Policy Exhibit 19.1 iCAD, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Company Information and Certain Transactions in Company Securities Purpose This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of iCAD, Inc., a Delaware corporation (including subsidiaries where applicable, the “Company”) and the handling of material conf |
|
| March 29, 2024 |
EXHIBIT 21.1 Subsidiaries of iCAD, Inc. Name Jurisdiction of Incorporation/Organization iCad France, LLC Delaware |
|
| March 29, 2024 |
Lease between Anita R. Jacques Revocable Trust, dated January 6, 2024 and iCAD, Inc. Exhibit 10.19 Lease Agreement Under the ownership under the trust of Anita R. Jacques Revocable Trust Dated 03/31/1994, of 211 Naticook Rd. Merrimack, NH. County of Hillsborough, and State of New Hampshire, (Lessor), hereby leases to iCAD, Inc. of 98 Spit Brook Road #100, Nashua, NH 03062 (Lessee). the Premises on the following terms: 1. PREMISES: 3,054 +/- Square feet in the building located at 2 |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-0934 |
|
| March 29, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, iCAD, Inc. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share (“Common Stock). General The following description of our capita |
|
| March 29, 2024 |
Exhibit 97.1 iCAD, INC. CLAWBACK POLICY 1. Introduction iCAD, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy. The Board of Directors (the “Board”) therefore adopts this policy |
|
| March 12, 2024 |
Exhibit 99.1 iCAD Announces Fiscal Fourth Quarter and Full-Year 2024 Financial Results Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 (GLOBE NEWSWIRE) - a global leader in clinically proven AI-powered solutions that enable medical p |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2024 iCAD, INC. |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2024 iCAD, INC. |
|
| February 14, 2024 |
ICAD / iCAD, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0086874-4sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* ICAD INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 44934S206 (CUSIP Number) Decembe |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 23, 2024 iCAD, INC. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2023 iCAD, INC. |
|
| November 13, 2023 |
Exhibit 99.1 iCAD Reports Financial Results for Third Quarter Ended September 30, 2023 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – November 13, 2023 (GLOBE NEWSWIRE) - iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2023 iCAD, INC. |
|
| October 23, 2023 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL ASSET PURCHASE AGREEMENT by and between ELEKTA INC., NUCLETRON OPERATIONS B.V., ICAD, INC., XOFT, INC. and XOFT SOLUTIONS, LLC Dated as of October 22, 2023 Table of Contents Page ART |
|
| October 23, 2023 |
UNAUDITED PRO FORMA FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA FINANCIAL INFORMATION On October 22, 2023, iCAD, Inc. (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), by and among (i) the Company, Xoft Solutions, LLC, a Delaware limited liability company, and Xoft, Inc., a Delaware corporation, each a wholly owned subsidiary of the Company (collectively with the Company, the “Sellers” and ea |
|
| October 23, 2023 |
Exhibit 99.1 iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta Xoft’s eBX system can now be offered to more clinics and cancer patients world-wide through Elekta’s extensive sales channels NASHUA, N.H., October 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions announced today that Elekta |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 22, 2023 iCAD, INC. |
|
| August 14, 2023 |
Exhibit 99.1 iCAD Reports Financial Results for Second Quarter Ended June 30, 2023 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 20 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2023 iCAD, INC. |
|
| August 11, 2023 |
Exhibit 1.1 iCAD, Inc. Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement August 11, 2023 Craig-Hallum Capital Group LLC 222 South 9th Street, Suite 350 Minneapolis, MN 55402 Ladies and Gentlemen: iCAD, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (“Craig-Hallum”), as follows: 1. Issuance an |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 11, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-273459 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2023) iCAD, INC. $25,000,000 Common Stock We have entered into an at the market offering agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”), relating to shares of our common stock, par value $0.01 per share, offered by this prospectus supplement a |
|
| August 7, 2023 |
August 7, 2023 Via EDGAR and E-mail Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 26, 2023 |
iCAD, INC. Issuer AND as Trustee INDENTURE Dated as of , 2023 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4 313(b) 5.4 313(c) 5.4 313(d) 5.4 314(a) 5.3, 14.12 314(c) 14.7(a) 314(e) 14.7(b) 315(a) 7.1 315(b) 7.14 315(c) 7.1 315 |
|
| July 26, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 26, 2023 As filed with the U.S. Securities and Exchange Commission on July 26, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iCAD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 02-0377419 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identific |
|
| July 26, 2023 |
Calculation of Filing Fee Tables Form S-3 (Form Type) iCAD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.0 |
|
| July 24, 2023 |
ICAD / Icad Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* ICAD INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 44934S206 (CUSIP Number) June 30, 2023 (Date of Event Which Requi |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2023 iCAD, INC. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2023 iCAD, INC. |
|
| May 15, 2023 |
Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2023 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – May 15, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. Highli |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 13, 2023 iCAD, INC. |
|
| April 17, 2023 |
Employment Agreement between iCAD, Inc. and Eric Lonnqvist, dated April 13, 2023 Exhibit 10.1 April 11, 2023 Eric Lonnqvist Dear Eric - We are pleased and excited to offer you employment with iCAD as Chief Financial Officer, reporting to Dana Brown, President & CEO with a start date of April 17, 2023, under the following terms. We look forward to your contribution and hope that together we can turn our new and growing company into a world-class supplier of innovative and clini |
|
| April 17, 2023 |
Exhibit 99.1 iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives Eric Lonnqvist as Chief Financial Officer, Vasu Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations Officer bolster the Company’s executive leadership team and accelerate the Company’s growth strategies NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD) |
|
| March 31, 2023 |
EXHIBIT 21.1 Subsidiaries of iCAD, Inc. Name Jurisdiction of Incorporation/Organization Xoft, Inc. Delaware Xoft Solutions, LLC Delaware iCad France, LLC Delaware iCad Italy, LLC Delaware |
|
| March 31, 2023 |
Separation agreement dated March 10, 2023, by and between iCAD, Inc. and Stacey Stevens Exhibit-10.q TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement and General Release (the “Separation Agreement”) is entered into by and between Stacey Stevens (“Employee”), an individual residing in the State of Massachusetts, and iCAD, Inc., a Delaware corporation (the “Company”). The Employee and the Company shall herein be referred to as the “Parties.” WHEREAS, Employe |
|
| March 31, 2023 |
Employment agreement dated March 10, 2023, by and between iCAD, Inc. and Dana Brown Exhibit 10.p EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the th day of March, 2023 (the “Effective Date”), between iCAD, Inc., a corporation with a principal place of business at 98 Spit Brook Road Suite 100, Nashua, NH 03062 (which hereinafter includes any parent, subsidiary and affiliate, and is collectively referred to as the “Company”), and D |
|
| March 31, 2023 |
Description of Registrant’s Securities Exhibit 4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, iCAD, Inc. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-0934 |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End Strategy focused on profitability by end of 2024, using current cash on hand New leadership to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2023 iCAD, INC. |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2023 iCAD, INC. |
|
| March 13, 2023 |
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023 EX-99.1 Exhibit 99.1 iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023 Company is exploring strategic options for its Therapy business line NASHUA, N.H., March 13, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2023 iCAD, INC. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2023 iCAD, INC. |
|
| March 13, 2023 |
EX-17.2 Exhibit 17.2 Tim Irish [email protected] 07772890460 10 March 2023 iCAD Inc, 98 Spit Brook Road Nashua, NH 03062 Dear Dana, I disagree with iCAD’s SEC disclosure regarding my resignation. The only reasons for my resignation were the two specified in my letter dated 6th March 2023. To imply any other reasons is disingenuous and an attempt to distract attention away from the two issues hig |
|
| March 13, 2023 |
EX-17.1 Exhibit 17.1 Tim Irish [email protected] 07772890460 6 March 2023 iCAD Inc, 98 Spit Brook Road Nashua, NH 03062 Dear Dana, Please accept this as notice of my resignation from the position of Non Employee Director at iCAD Inc effective immediately. The reasons for my resignation are two-fold; in my personal opinion the company’s direction and governance are misguided, and I am personally |
|
| February 14, 2023 |
ICAD / iCAD Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0081954-9sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* ICAD INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 44934S206 (CUSIP Number) Decembe |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| February 3, 2023 |
Executive Chairman Agreement, dated January 6, 2023. Exhibit 10.1 EXECUTIVE CHAIRMAN AGREEMENT This Executive Chairman Agreement (the “Agreement”) is entered into effective as of January 6, 2023 (the “Effective Date”), by and between ICAD, INC., a Delaware corporation (the “Company”), and DANA BROWN (the “Executive”). WHEREAS, the Company desires that the Executive be retained to serve in the capacity of Executive Chairman of the Board of Directors |
|
| January 24, 2023 |
Exhibit 99.1 iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA, N.H. – January 23, 2023 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announ |
|
| January 24, 2023 |
Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is made effective as of January 18, 2023(the “Effective Date”), by and between iCAD, Inc., a Delaware corporation having a principal place of business at 98 Spit Brook Road, Suite 100, Nashua, NH 03062 (“iCAD”), and Woodcliff Advisors, LLC with its principal being Daniel J. Shea, with its principal places of business at |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 19, 2023 iCAD, INC. |
|
| January 12, 2023 |
iCAD Announces Board of Directors Transition Dana Brown named Executive Chair of the Board Exhibit 99.1 iCAD Announces Board of Directors Transition Dana Brown named Executive Chair of the Board NASHUA, N.H. – January 11, 2023—iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors. Ms. Brown has been a non-executive board member s |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 6, 2023 iCAD, INC. |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2022 iCAD, INC. |
|
| December 9, 2022 |
ICAD / iCAD Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 ICAD INC. (Name of Issuer) Common Shares (Title of Class of Securities) 44934S206 (CUSIP Number) November 28th, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 29, 2022 |
Exhibit 10.1 December 7, 2006 Ms. Darlene Deptula-Hicks iCAD 4 Townsend West, Suite 17 Nashua, NH 03063 Re: Lease Agreement dated December 6, 2006 98 Spit Brook Road Nashua, NH 03062 Dear Ms. Deptula-Hicks: Enclosed please find one (1) fully-executed original of the above-referenced document for your files. Thank you for all your cooperation and assistance with completing this transaction. If I ma |
|
| November 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2022 iCAD, INC. |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2022 iCAD, INC. |
|
| November 10, 2022 |
Exhibit 99.1 ICAD REPORTS FINANCIAL RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2022 Company implements corporate strategic realignment Partnership-based recurring revenue model anticipated to drive future growth Cost structure reduction to decrease expenses by over $3 million annually Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. ? November 10, 2022 ? iCAD, Inc. ( |
|
| November 2, 2022 |
ICAD / iCAD Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* ICAD INC. (Name of Issuer) Common Stock (Title of Class of Securities) 44934S206 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of |
|
| August 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 15, 2022 |
Exhibit 10.1 LEASE BETWEEN THE IRVINE COMPANY LLC AND ICAD, INC. LEASE THIS LEASE is made as of the day of June 2012, by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, hereafter called ?Landlord, and ICAD, INC., a Delaware corporation, hereafter called ?Tenant.? 9th Each reference in this Lease to the ?Basic Lease Provisions shall mean and refer to the following collecti |
|
| August 10, 2022 | ||
| August 10, 2022 |
iCAD Reports Financial Results For Second Quarter 2022 Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2022 iCAD, INC. |
|
| July 6, 2022 |
ICAD / iCAD Inc / HIRSCHMAN ORIN Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ICAD INC. (Name of Issuer) Common Shares (Title of Class of Securities) 44934S206 (CUSIP Number) June 29th, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ? Rule 13d-1(b) ? Rule 13d-1( |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2022 iCAD, INC. |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| June 1, 2022 |
Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?) is made effective as of May 24, 2022 (the ?Effective Date?), by and between iCAD, Inc., a Delaware corporation having a principal place of business at 98 Spit Brook Road, Suite 100, Nashua, NH 03062 (?iCAD?), and Daley and Associates, LLC, an organization with an address at One Financial Center, Boston, MA 02111 (?Contr |
|
| June 1, 2022 |
Exhibit 99.1 iCAD Announces CFO Transition Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately NASHUA, N.H., May 25, 2022 ? iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2022 iCAD, INC. |
|
| May 26, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 25, 2022 iCAD, INC. |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 11, 2022 |
Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2022 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. ? May 11, 2022 ? iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022. Highli |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 11, 2022 iCAD, INC. |
|
| May 9, 2022 |
SD 1 d343611dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICAD, INC. (Exact name of registrant as specified in its charter) Delaware 001-09341 02-0377419 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 98 Spit Brook Road, Suite 100, Nashua, NH 0306 |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 21, 2022 |
Exhibit 99.1 iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions Company expects preliminary estimated revenue to be $7.5 million Timothy Norris Irish Appointed Chairman of the Board of Directors, Successor CFO search underway NASHUA, N.H. ? April 21, 2022 ? iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy soluti |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2022 iCAD, INC. |
|
| March 29, 2022 |
EXHIBIT 21 Subsidiaries of iCAD, Inc. Name Jurisdiction of Incorporation/Organization Xoft, Inc. Delaware Xoft Solutions, LLC Delaware iCad France, LLC Delaware iCad Italy, LLC Delaware |
|
| March 29, 2022 |
Description of Registrant’s Securities Exhibit 4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, iCAD, Inc. |
|
| March 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-093 |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 22, 2022 iCAD, INC. |
|
| March 28, 2022 |
Employment Agreement, effective March 1, 2022 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 1st day of March, 2022 (the ?Effective Date?), between iCAD, Inc., a corporation with a principal place of business at 98 Spit Brook Road Suite 100, Nashua, NH 03062 (which hereinafter includes any parent, subsidiary and affiliate, and is collectively referred to as the ?Company?), and |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2022 iCAD, INC. |
|
| February 28, 2022 |
Exhibit 99.1 iCAD REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2021 Launched ProFound AI? Risk, the world?s first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft? Brain IORT in recurrent glioblastoma (GBM) as published in Surgical Neurology International - Company to Host Conference Ca |
|
| February 14, 2022 |
ICAD / iCAD Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* ICAD INC. (Name of Issuer) Common Stock (Title of Class of Securities) 44934S206 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of |
|
| February 11, 2022 |
ICAD / iCAD Inc / Portolan Capital Management, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. 2 )* iCAD, Inc. (Name of Issuer) Common (Title of Class of Securities) 44934S206 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2022 iCAD, INC. |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 4, 2022 iCAD, INC. |
|
| January 6, 2022 |
Exhibit 99.1 iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues Company expects preliminary estimated Q4 2021 revenues to be between $7.8-$8.0 million NASHUA, N.H., January 4, 2022 ? iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and ful |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 6, 2021 iCAD, INC. |
|
| November 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 9, 2021 |
Exhibit 99.1 ICAD REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2021 - Third Quarter Revenues of $9.4 Million Represented 20% Sequential Quarter Growth over the Second Quarter of 2021, Driven by 26% Growth in Detection Revenue and 10% Growth in Therapy Revenue ? - Third Quarter 2021 Revenues Represented 31% Growth Compared to the Third Quarter 2020 ? - Improving Enterprise Sales in |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2021 iCAD, INC. |
|
| August 6, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 4th day of August, 2021 (the ?Effective Date?), between iCAD, Inc., a corporation with a principal place of business at 98 Spit Brook Road Suite 100, Nashua, NH 03062 (which hereinafter includes any parent, subsidiary and affiliate, and is collectively referred to as the ?Company?), and |
|
| August 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 2, 2021 iCAD, INC. |
|
| August 6, 2021 |
Certificate of Incorporation, as amended. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF HOWTEK, INC. FIRST: The name of the Corporation is Howtek, Inc. SECOND: The address of its registered office in the State of Delaware is 100 West 10th St., Wilmington, Delaware, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company. THIRD: The nature of the business or purposes to be conducted or promoted |
|
| August 6, 2021 |
2016 Stock Incentive Plan, as amended Exhibit 10.1 iCAD, INC. 2016 STOCK INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iCad, Inc. 2016 Stock Incentive Plan (the ?Plan?). The purpose of the Plan is to align the interests of the officers, employees, Non-Employee Directors and Consultants of iCad, Inc. (the ?Company?) and its Subsidiaries upon whose judgment, initiative and eff |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2021 iCAD, INC. |
|
| August 5, 2021 |
Exhibit 99.1 ICAD REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021 Conference Call Today at 4:30 PM ET NASHUA, N.H. ? August 5, 2021 ? iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2021. Revenues for the three-month |
|
| July 21, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ICAD, INC. Adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware The undersigned, being a duly authorized officer of iCAD, Inc. (the ?Corporation?), a corporation existing under the laws of the State of Delaware, does hereby certify as follows: 1. The Certificate of In |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2021 iCAD, INC. |
|
| July 21, 2021 |
Amendment to 2016 Stock Incentive Plan, as amended Exhibit 10.1 AMENDMENT TO THE 2016 STOCK INCENTIVE PLAN OF ICAD, INC. This Amendment (this ?Amendment?) to the iCAD, Inc. 2016 Stock Incentive Plan (as may be amended from time to time, the ?Plan?) is made as of July 15, 2021 (the ?Effective Date?). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Plan. WHEREAS, Section 18 of the Plan provides |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICAD, INC. (Exact name of registrant as specified in its charter) Delaware 001-09341 02-0377419 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 98 Spit Brook Road, Suite 100, Nashua, NH 03062 (Address of principal |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-0 |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2021 iCAD, INC. |
|
| April 28, 2021 |
Consulting Agreement, dated April 16, 2021, by and between iCAD, Inc. and Charles Carter CONSULTING Agreement THIS CONSULTING AGREEMENT (this ?Agreement?) is made effective as of April 16, 2021 (the ?Effective Date?), by and between iCAD, Inc. |
|
| April 28, 2021 |
ICAD REPORTS FINANCIAL RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2021 First Quarter Revenues of $8. |
|
| April 5, 2021 |
iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition Company expects preliminary estimated revenues to exceed $8. |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2021 iCAD, INC. |
|
| March 15, 2021 |
EXHIBIT 21 Subsidiaries of iCAD, Inc. Name Jurisdiction of Incorporation/Organization Xoft, Inc. Delaware Xoft Solutions, LLC Delaware PMDE ICAD France |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09341 iCAD, INC. (Exa |
|
| March 4, 2021 |
1,222,222 Shares of Common Stock ICAD, INC. UNDERWRITING AGREEMENT March 2, 2021 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: iCAD, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), propose |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 2, 2021 iCAD, INC. |
|
| March 4, 2021 |
iCAD Announces Proposed Public Offering of Common Stock iCAD Announces Proposed Public Offering of Common Stock NASHUA, NH, March 2, 2021 - iCAD, Inc. |
|
| March 4, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-235887 and 333-253808 PROSPECTUS SUPPLEMENT (To Prospectus dated January 31, 2020) 1,222,222 Shares Common Stock We are offering 1,222,222 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol ?ICAD.? On March 1, 2021, the last reported sale price of shares of our common stock on the Nasdaq Capita |
|
| March 4, 2021 |
iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock NASHUA, NH, March 3, 2021 - iCAD, Inc. (the ?Company?, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per share. The gross p |
|
| March 2, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 2, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-235887 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are |
|
| March 2, 2021 |
As filed with the Securities and Exchange Commission on March 2, 2021 Registration No. |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2021 iCAD, INC. |
|
| February 24, 2021 |
iCAD REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2020 Fourth Quarter Revenues of $10. |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2021 iCAD, INC. |
|
| February 19, 2021 |
Amendment to 2016 Stock Incentive Plan as amended December 2018 amendment to the ICAD, Inc. 2016 Stock Incentive Plan as amended December 2018 The 2016 Stock Incentive Plan as amended December 2018 (the ?Plan?) of iCAD, Inc. (the ?Company?) is hereby amended as set forth below, effective upon approval by the stockholders of the Company. I. The first sentence of Section 3(a) of the Plan is hereby amended to read as follows: The maximum number of shares of Stock |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. 1 )* iCAD, Inc. (Name of Issuer) Common (Title of Class of Securities) 44934S206 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. )* iCAD, Inc. (Name of Issuer) Common (Title of Class of Securities) 44934S206 (CUSIP Number) December 17, 2020 (Date of Event Which Requires Filing of this S |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2020 iCAD, INC. |
|
| November 5, 2020 |
EX-99.1 2 d914380dex991.htm EX-99.1 Exhibit 99.1 iCAD REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively Net Loss Improved by $1.2 million to $1.8 million in the Third Quarter of 2020 as Compared to $3.0 m |
|
| August 7, 2020 |
EX-10.1 Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 16, 2020, by and between WESTERN ALLIANCE BAN |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2020 iCAD, INC. |
|
| August 4, 2020 |
iCAD REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe Recent 50 System Agreement with SimonMed Imaging Highlights Significant Value of ProFound AI Solution Expert Panel Reviews Compelling Clinical Data on Xoft® Brain IORT Conference Call Today at 4:30 p. |
|
| July 6, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 1, 2020 iCAD, INC. |
|
| July 2, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 26, 2020 iCAD, INC. |
|
| June 24, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 22, 2020 iCAD, INC. |
|
| May 29, 2020 |
Employment Agreement, dated May 26, 2020, between iCAD, Inc. and R. Scott Areglado EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 26th day of May, 2020 (the “Effective Date”), between iCAD, Inc. |
|
| May 29, 2020 |
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 26th day of May, 2020 (the “Effective Date”), between iCAD, Inc. |
